Treatment
Baricitinib clinical trials
We’re tracking 30 recruiting studies that include Baricitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07279688RecruitingPhase 3
Baricitinib plus steroids for polymyalgia rheumatica
This trial tests if adding baricitinib (a pill that calms inflammation) to standard steroids works better than steroids alone for people with polymyalgia rheumatica. It aims to improve symptoms and reduce steroid side effects.
Aix-en-ProvenceAges 50 years+ - NCT07262983RecruitingPhase 1
Baricitinib for Job syndrome with lupus or eczema
This study tests if baricitinib, a pill that changes how your immune system works, is safe and tolerable for people with Job syndrome who also have lupus-like disease or severe eczema. It might offer a new treatment option for these skin and immune problems.
Bethesda, MarylandAges 12–120 - NCT07222137RecruitingPhase 3
Baricitinib to delay type 1 diabetes in at-risk people
This trial tests if baricitinib, a pill that calms the immune system, can slow down or delay the onset of type 1 diabetes in children and adults who are at high risk. It is for people whose blood sugar is already starting to rise but who do not yet need insulin.
Santa Barbara, CaliforniaAges 1–35 - NCT03773965RecruitingPhase 3
Baricitinib study for kids with juvenile arthritis
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
RosarioAges 1–18 - NCT07222332RecruitingPhase 3
Baricitinib for new type 1 diabetes to save insulin-making cells
This trial tests if baricitinib, a pill that calms the immune system, can protect the remaining insulin-making cells in people newly diagnosed with type 1 diabetes. If it works, you might keep making some of your own insulin longer.
Aurora, ColoradoAges 1–35 - NCT06548802RecruitingPhase 1/Phase 2
Baricitinib for lung injury after brain bleed
This trial tests a pill called baricitinib to see if it helps people recover from lung injury after a brain bleed. It is for patients who need a breathing machine due to ARDS that started within a week of the bleed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT05452564RecruitingPhase 2
Baricitinib to help reduce HIV in the brain
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
Atlanta, GeorgiaAges 18–65 - NCT05723198RecruitingPhase 3
Baricitinib for severe childhood hair loss from alopecia areata
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
Birmingham, AlabamaAges 6–17 - NCT06065046RecruitingPhase 2
Baricitinib for traumatic brain bleeding
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
Xi'an, ShaanxiAges 18–80 - NCT06631287RecruitingPhase 3
Testing baricitinib for persistent long COVID symptoms
This trial tests whether the anti-inflammatory drug baricitinib can improve persistent long COVID symptoms like brain fog, fatigue, and shortness of breath. You may qualify if you had COVID-19 at least 6 months ago and still have bothersome symptoms that affect your daily life.
Tucson, ArizonaAges 18 years+ - NCT06849908RecruitingPhase 2
Baricitinib for treating intestinal Behçet's disease
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
Beijing, Beijing MunicipalityAges 18–65 - NCT06923072RecruitingPhase 2
Baricitinib for neurological Kohlmeier-Degos disease
This trial tests if the drug baricitinib can help people with Degos disease that has affected their brain or nerves. It aims to control inflammation and improve symptoms.
Bethesda, MarylandAges 18–99 - NCT06936215RecruitingPhase 3
Baricitinib vs methotrexate for skin tightening in scleroderma
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
DhakaAges 18 years+ - NCT06381661RecruitingPhase 2
Personalized treatment for sepsis in children and adults
This trial is testing several different treatments to find the best one for each person with sepsis. It looks at specific 'treatable traits' like inflammation, blood clotting problems, or immune system issues to match you with the right therapy. The goal is to improve recovery and survival.
DijonAges 9 months+ - NCT06687551RecruitingPhase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Toulouse, OccitanieAges 18–65 - NCT03414502RecruitingPhase 3
Predictors of Response to DMARDs in Rheumatoid Arthritis
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
Omaha, NebraskaAges 19 years+ - NCT04381936RecruitingPhase 3
Testing COVID-19 or pneumonia treatments in hospitalized patients
This trial tests different treatments for serious lung infections in people who are already in the hospital. It may help doctors learn which treatment works best for recovery and survival when pneumonia-like illness is suspected.
BrusselsAges birth+ - NCT05003310Recruiting
Splenic stimulation study for active rheumatoid arthritis
This study tests a treatment that stimulates the spleen to help calm symptoms of active rheumatoid arthritis (RA). It’s mainly for people whose RA has not improved enough after several newer arthritis medicines.
Anniston, AlabamaAges 22–75 - NCT05849038RecruitingPhase 2
Treating inflammation to improve depression in HIV
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
Atlanta, GeorgiaAges 18–65 - NCT05955066RecruitingPhase 4
Testing a JAK inhibitor to help RA joint erosion heal
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
Hong Kong, Hong KongAges 18–65 - NCT06490757RecruitingPhase 2
Testing a pill for large inflamed liver growths
This trial tests a daily pill (baricitinib) to shrink large, inflamed liver growths called inflammatory hepatocellular adenomas. It may be an option for people who have at least one growth larger than 5 cm and who are not using estrogen-containing birth control.
BobignyAges 18–65 - NCT06573593Recruiting
JAK inhibitors for children with alopecia areata
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
Hangzhou, ZhejiangAges 2–80 - NCT06768840RecruitingPhase 2/Phase 3
New treatment for active vitiligo, checking blood markers
This trial tests a new treatment for people with active generalized vitiligo covering more than 5% of their body (not counting hands and feet). It also looks at a protein in the blood called s100B to see how it relates to the condition and treatment response.
QinaAges 10–75
What Baricitinib is being studied for
Conditions with recruiting Baricitinib studies.
Common questions
- Are there clinical trials studying Baricitinib?
- Yes. Clin2 currently lists 30 recruiting studies that include Baricitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Baricitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Baricitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Baricitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.